{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:26:50Z","timestamp":1791358010471,"version":"4.3.1"},"reference-count":134,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.neo.2020.09.005","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T21:13:30Z","timestamp":1603487610000},"page":"725-744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":167,"title":["ONC201 and imipridones: Anti-cancer compounds with clinical efficacy"],"prefix":"10.1016","volume":"22","author":[{"given":"Varun Vijay","family":"Prabhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abed","family":"Rahman Kawakibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Ralff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakash","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isacco","family":"Ferrarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Borsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-I","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua N.","family":"Honeyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Tavora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedito","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Raufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Huntington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Carlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Safran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila A.","family":"Seyhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohinton S.","family":"Tarapore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Schalop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stogniew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua E.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Oster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafik S.","family":"El-Deiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neo.2020.09.005_b0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrc2069","article-title":"G-protein-coupled receptors and cancer","volume":"7","author":"Dorsam","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.neo.2020.09.005_b0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jsps.2013.07.007","article-title":"Targeting G protein coupled receptor-related pathways as emerging molecular therapies","volume":"23","author":"Ghanemi","year":"2015","journal-title":"Saudi Pharm J"},{"issue":"1","key":"10.1016\/j.neo.2020.09.005_b0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrd3320","article-title":"G protein-coupled receptors: novel targets for drug discovery in cancer","volume":"10","author":"Lappano","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.neo.2020.09.005_b0020","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrc3521","article-title":"The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer","volume":"13","author":"O'Hayre","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.neo.2020.09.005_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17050707","article-title":"G protein-coupled receptor signaling in stem cells and cancer","volume":"17","author":"Lynch","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.neo.2020.09.005_b0030","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: new agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neo.2020.09.005_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.03.014","article-title":"Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality","author":"Ishizawa","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2020.09.005_b0040","doi-asserted-by":"crossref","DOI":"10.1534\/genetics.119.302851","article-title":"Imipridone anticancer compounds ectopically activate the ClpP protease and represent a new scaffold for antibiotic development","author":"Jacques","year":"2020","journal-title":"Genetics"},{"issue":"6","key":"10.1016\/j.neo.2020.09.005_b0045","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ccell.2015.05.004","article-title":"Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia","volume":"27","author":"Cole","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2020.09.005_b0050","doi-asserted-by":"crossref","DOI":"10.1021\/acschembio.9b00222","article-title":"Mitochondrial protease ClpP is a target for the anticancer compounds ONC201 and related analogues","author":"Graves","year":"2019","journal-title":"ACS Chem Biol"},{"issue":"Pt 1","key":"10.1016\/j.neo.2020.09.005_b0055","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1042\/bj3310309","article-title":"A human homologue of Escherichia coli ClpP caseinolytic protease: recombinant expression, intracellular processing and subcellular localization","volume":"331","author":"Corydon","year":"1998","journal-title":"Biochem J"},{"key":"10.1016\/j.neo.2020.09.005_b0060","article-title":"Monoamines in Glioblastoma: complex biology with therapeutic potential","author":"Caragher","year":"2017","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.neo.2020.09.005_b0065","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/sj.bjc.6603259","article-title":"Cancer risk among users of neuroleptic medication: a population-based cohort study","volume":"95","author":"Dalton","year":"2006","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.neo.2020.09.005_b0070","first-page":"697","article-title":"Parkinson's disease and cancer risk: a systematic review and meta-analysis","volume":"21","author":"Bajaj","year":"2010","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.neo.2020.09.005_b0075","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.77","article-title":"Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data","volume":"6","author":"Cheng","year":"2015","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1016\/j.neo.2020.09.005_b0080","doi-asserted-by":"crossref","first-page":"882","DOI":"10.18632\/oncotarget.1801","article-title":"Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"issue":"36","key":"10.1016\/j.neo.2020.09.005_b0085","doi-asserted-by":"crossref","first-page":"13485","DOI":"10.1073\/pnas.0605993103","article-title":"Dopamine targets cycling B cells independent of receptors\/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma","volume":"103","author":"Meredith","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.neo.2020.09.005_b0090","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1523\/JNEUROSCI.1589-18.2018","article-title":"Activation of dopamine receptor 2 prompts transcriptomic and metabolic plasticity in glioblastoma","volume":"39","author":"Caragher","year":"2019","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.neo.2020.09.005_b0095","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1124\/jpet.119.256818","article-title":"Cancer and the dopamine D2 receptor: a pharmacological perspective","volume":"370","author":"Weissenrieder","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.neo.2020.09.005_b0100","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.7150\/jca.27780","article-title":"The prospective value of dopamine receptors on bio-behavior of tumor","volume":"10","author":"Wang","year":"2019","journal-title":"J Cancer"},{"issue":"2","key":"10.1016\/j.neo.2020.09.005_b0105","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/jcp.25079","article-title":"Genetic and functional analysis of polymorphisms in the human dopamine receptor and transporter genes in small cell lung cancer","volume":"231","author":"Cherubini","year":"2016","journal-title":"J Cell Physiol"},{"issue":"5","key":"10.1016\/j.neo.2020.09.005_b0110","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.18632\/oncotarget.1835","article-title":"Dopamine signaling: target in glioblastoma","volume":"5","author":"Bartek","year":"2014","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.neo.2020.09.005_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bph.12906","article-title":"Dopamine receptors \u2013 IUPHAR Review 13","volume":"172","author":"Beaulieu","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.neo.2020.09.005_b0120","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev.physiol.69.022405.154749","article-title":"Beta-arrestins and cell signaling","volume":"69","author":"DeWire","year":"2007","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"10.1016\/j.neo.2020.09.005_b0125","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1038\/s41467-019-12928-6","article-title":"A Bayesian machine learning approach for drug target identification using diverse data types","volume":"10","author":"Madhukar","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.neo.2020.09.005_b0130","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/1078-0432.CCR-18-2572","article-title":"Dopamine receptor D5 is a modulator of tumor response to dopamine receptor D2 antagonism","volume":"25","author":"Prabhu","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"Suppl 6","key":"10.1016\/j.neo.2020.09.005_b0135","article-title":"Receptor pharmacology of ONC201: The first bitopic DRD2 antagonist for clinical neuro-oncology (EXTH-33)","volume":"21","author":"Free","year":"2019","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.neo.2020.09.005_b0140","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.neo.2017.10.002","article-title":"Role of dopamine receptors in the anticancer activity of ONC201","volume":"20","author":"Kline","year":"2018","journal-title":"Neoplasia"},{"issue":"21","key":"10.1016\/j.neo.2020.09.005_b0145","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-18-1040","article-title":"Metabolic reprogramming by dual AKT\/ERK inhibition through imipridones elicits unique vulnerabilities in glioblastoma","volume":"24","author":"Ishida","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.neo.2020.09.005_b0150","doi-asserted-by":"crossref","first-page":"18454","DOI":"10.18632\/oncotarget.24862","article-title":"ONC201 kills breast cancer cells in vitro by targeting mitochondria","volume":"9","author":"Greer","year":"2018","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.neo.2020.09.005_b0155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.neo.2020.09.005_b0160","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.11814","article-title":"Discovery and clinical introduction of first-in-class imipridone ONC201","author":"Allen","year":"2016","journal-title":"Oncotarget"},{"issue":"171","key":"10.1016\/j.neo.2020.09.005_b0165","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004828","article-title":"Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects","volume":"5","author":"Allen","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neo.2020.09.005_b0170","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-015-0346-9","article-title":"Identification of TRAIL-inducing compounds highlights small molecule ONC201\/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway","volume":"14","author":"Allen","year":"2015","journal-title":"Mol Cancer"},{"issue":"415","key":"10.1016\/j.neo.2020.09.005_b0175","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aac4374","article-title":"ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2alpha kinases","volume":"9","author":"Kline","year":"2016","journal-title":"Sci Signal"},{"issue":"415","key":"10.1016\/j.neo.2020.09.005_b0180","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aac4380","article-title":"ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies","volume":"9","author":"Ishizawa","year":"2016","journal-title":"Sci Signal"},{"issue":"7","key":"10.1016\/j.neo.2020.09.005_b0185","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1158\/0008-5472.CAN-13-3451","article-title":"Small-molecule ONC201\/TIC10 targets chemotherapy-resistant colorectal cancer stem-like cells in an Akt\/Foxo3a\/TRAIL-dependent manner","volume":"75","author":"Prabhu","year":"2015","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.neo.2020.09.005_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180541","article-title":"Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors","volume":"12","author":"Prabhu","year":"2017","journal-title":"PLoS ONE"},{"issue":"34","key":"10.1016\/j.neo.2020.09.005_b0195","doi-asserted-by":"crossref","first-page":"36456","DOI":"10.18632\/oncotarget.5505","article-title":"TIC10\/ONC201 synergizes with Bcl-2\/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo","volume":"6","author":"Karpel-Massler","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.neo.2020.09.005_b0200","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1172\/JCI96711","article-title":"Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment","volume":"128","author":"Wagner","year":"2018","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.neo.2020.09.005_b0205","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/83416","article-title":"Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells","volume":"7","author":"Takeda","year":"2001","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.neo.2020.09.005_b0210","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/CJI.0b013e31829b4493","article-title":"Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells","volume":"36","author":"Sheard","year":"2013","journal-title":"J Immunother"},{"issue":"6","key":"10.1016\/j.neo.2020.09.005_b0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065860","article-title":"Dopamine receptors modulate cytotoxicity of natural killer cells via cAMP-PKA-CREB signaling pathway","volume":"8","author":"Zhao","year":"2013","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.neo.2020.09.005_b0220","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.4049\/jimmunol.1401114","article-title":"Dopamine inhibits the effector functions of activated NK cells via the upregulation of the D5 receptor","volume":"193","author":"Mikulak","year":"2014","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.neo.2020.09.005_b0225","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.180.1.163","article-title":"Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition","volume":"180","author":"Hallett","year":"2008","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.neo.2020.09.005_b0230","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1534664","article-title":"Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5","volume":"8","author":"Carlsten","year":"2019","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.neo.2020.09.005_b0235","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2249.2008.03818.x","article-title":"Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition","volume":"155","author":"Ames","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.neo.2020.09.005_b0240","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00262-016-1804-y","article-title":"Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway","volume":"65","author":"Bommarito","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"10.1016\/j.neo.2020.09.005_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143082","article-title":"First-in-class small molecule ONC201 induces DR5 and cell death in tumor but not normal cells to provide a wide therapeutic index as an anti-cancer agent","volume":"10","author":"Allen","year":"2015","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.neo.2020.09.005_b0250","first-page":"1551","article-title":"ONC201 demonstrates anti-tumorigenic and anti-metastatic activity in uterine serous carcinoma in vitro","volume":"8","author":"Fang","year":"2018","journal-title":"Am J Cancer Res"},{"issue":"19","key":"10.1016\/j.neo.2020.09.005_b0255","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1080\/15384101.2017.1325046","article-title":"Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212","volume":"16","author":"Wagner","year":"2017","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.neo.2020.09.005_b0260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13046-018-0671-0","article-title":"Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms","volume":"37","author":"Wagner","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"suppl_6","key":"10.1016\/j.neo.2020.09.005_b0265","doi-asserted-by":"crossref","first-page":"vi81","DOI":"10.1093\/neuonc\/nox168.334","article-title":"H3 K27M mutant gliomas are selectively killed by ONC201, a small molecule inhibitor of dopamine receptor D2","volume":"19","author":"Chi","year":"2017","journal-title":"Neuro-Oncology"},{"issue":"9","key":"10.1016\/j.neo.2020.09.005_b0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162133","article-title":"Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study","volume":"11","author":"Feng","year":"2016","journal-title":"PLoS ONE"},{"issue":"13 Suppl","key":"10.1016\/j.neo.2020.09.005_b0275","article-title":"ONC201 induction of apoptosis in hPheo1 cell line supports use of this oral agent in ongoing phase 2 clinical trial against neuroendocrine tumors (NCT03034200)","volume":"78","author":"Proudfit","year":"2018","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.neo.2020.09.005_b0280","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101505","article-title":"Current Management of Pheochromocytoma\/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine","volume":"11","author":"Nolting","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.neo.2020.09.005_b0285","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.bbrc.2016.08.126","article-title":"mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity","volume":"478","author":"Jin","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"10.1016\/j.neo.2020.09.005_b0290","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1158\/1535-7163.MCT-17-0121","article-title":"ONC201 demonstrates antitumor effects in both triple-negative and non-triple-negative breast cancers through TRAIL-dependent and TRAIL-independent mechanisms","volume":"16","author":"Ralff","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"10.1016\/j.neo.2020.09.005_b0295","doi-asserted-by":"crossref","first-page":"21626","DOI":"10.18632\/oncotarget.15451","article-title":"ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells","volume":"8","author":"Yuan","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.neo.2020.09.005_b0300","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1541-7786.MCR-17-0614","article-title":"ONC201 targets AR and AR-V7 signaling, reduces PSA, and synergizes with everolimus in prostate cancer","volume":"16","author":"Lev","year":"2018","journal-title":"Mol Cancer Res"},{"issue":"5","key":"10.1016\/j.neo.2020.09.005_b0305","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.neo.2018.02.006","article-title":"Efficacy of ONC201 in desmoplastic small round cell tumor","volume":"20","author":"Hayes-Jordan","year":"2018","journal-title":"Neoplasia"},{"issue":"17","key":"10.1016\/j.neo.2020.09.005_b0310","doi-asserted-by":"crossref","first-page":"28385","DOI":"10.18632\/oncotarget.16073","article-title":"Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells","volume":"8","author":"Cheng","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.neo.2020.09.005_b0315","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2012.03.049","article-title":"Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells","volume":"149","author":"Sachlos","year":"2012","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.neo.2020.09.005_b0320","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/bloodadvances.2018015677","article-title":"A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia","volume":"2","author":"Aslostovar","year":"2018","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.neo.2020.09.005_b0325","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.neo.2017.07.009","article-title":"The imipridone ONC201 induces apoptosis and overcomes chemotherapy resistance by up-regulation of bim in multiple myeloma","volume":"19","author":"Tu","year":"2017","journal-title":"Neoplasia"},{"issue":"15","key":"10.1016\/j.neo.2020.09.005_b0330","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1080\/15384101.2015.1054086","article-title":"ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells","volume":"14","author":"Talekar","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.neo.2020.09.005_b0335","first-page":"1","article-title":"Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies","author":"Prabhu","year":"2017","journal-title":"Cell Cycle"},{"issue":"37","key":"10.1016\/j.neo.2020.09.005_b0340","doi-asserted-by":"crossref","first-page":"61761","DOI":"10.18632\/oncotarget.18688","article-title":"ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK\/STAT and NF-kappaB pathways","volume":"8","author":"Ni","year":"2017","journal-title":"Oncotarget"},{"issue":"13 Suppl","key":"10.1016\/j.neo.2020.09.005_b0345","article-title":"Synergistic antitumor effect of ONC201 in combination with radiation therapy","volume":"78","author":"Zhou","year":"2018","journal-title":"Cancer Res"},{"issue":"13 Suppl","key":"10.1016\/j.neo.2020.09.005_b0350","article-title":"ONC201 shows efficacy in BRCA-deficient cancer cells and synergy with PARP inhibitors in glioblastoma, breast, prostate, and ovarian cancers","volume":"77","author":"Baumeister","year":"2017","journal-title":"Cancer Res"},{"issue":"3 Supplement","key":"10.1016\/j.neo.2020.09.005_b0355","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/j.ijrobp.2018.07.666","article-title":"Imipridone (ONC201) and radiation therapy combination shows promise in breast cancer treatment","volume":"102","author":"Jhawar","year":"2018","journal-title":"Int J Radiat Oncol"},{"issue":"13 Supplement","key":"10.1016\/j.neo.2020.09.005_b0360","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/1538-7445.AM2019-258","article-title":"Abstract 258: recombinant human TRAIL or a DR5 agonistic antibody convert the response of non-triple negative breast cancer cells to ONC201 from anti-proliferative to apoptotic","volume":"79","author":"Ralff","year":"2019","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.neo.2020.09.005_b0365","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1158\/0008-5472.CAN-14-2356","article-title":"Genetic and pharmacological screens converge in identifying FLIP, BCL2, and IAP proteins as key regulators of sensitivity to the TRAIL-inducing anticancer agent ONC201\/TIC10","volume":"75","author":"Allen","year":"2015","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.neo.2020.09.005_b0370","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bbrc.2016.05.106","article-title":"The preclinical evaluation of TIC10\/ONC201 as an anti-pancreatic cancer agent","volume":"476","author":"Zhang","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"47","key":"10.1016\/j.neo.2020.09.005_b0375","doi-asserted-by":"crossref","first-page":"81776","DOI":"10.18632\/oncotarget.20819","article-title":"Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78\/BIP","volume":"8","author":"Lev","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2020.09.005_b0380","article-title":"Modulating the unfolded protein response: Impacts of radiation on the response of prostate cancer cells to ONC201","author":"Amoroso","year":"2019","journal-title":"bioRxiv"},{"issue":"suppl_6","key":"10.1016\/j.neo.2020.09.005_b0385","doi-asserted-by":"crossref","first-page":"vi72","DOI":"10.1093\/neuonc\/noy148.295","article-title":"ONC201 in combination with radiation exhibits synergistic efficacy in high grade gliomas and other advanced cancers","volume":"20","author":"Tarapore","year":"2018","journal-title":"Neuro-Oncology"},{"issue":"13 Suppl","key":"10.1016\/j.neo.2020.09.005_b0390","article-title":"Abstract 262: Anti-tumorigenic effect of ONC201 is enhanced by combination treatment with TRAIL or a DR5 agonist in endometrial cancer in vitro","volume":"79","author":"Ray","year":"2019","journal-title":"Cancer Res"},{"issue":"Suppl_6","key":"10.1016\/j.neo.2020.09.005_b0395","article-title":"EXTH-57. Preclinical combination of ONC201 with radiotherapy or temozolomide in GBM, DIPG and ATRT cell lines results in dopamine receptor antagonism, atf4 induction and cell death","volume":"21","author":"Zhou","year":"2019","journal-title":"Neuro-Oncology"},{"issue":"suppl_6","key":"10.1016\/j.neo.2020.09.005_b0400","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noy148.295","article-title":"DDIS-16. ONC201 in combination with radiation exhibits synergistic efficacy in high grade gliomas and other advanced cancers","volume":"20","author":"Tarapore","year":"2018","journal-title":"Neuro-Oncology"},{"issue":"6","key":"10.1016\/j.neo.2020.09.005_b0405","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1158\/1535-7163.MCT-07-0010","article-title":"5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells","volume":"6","author":"Kiziltepe","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.neo.2020.09.005_b0410","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.celrep.2016.05.052","article-title":"Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics","volume":"15","author":"Navarro","year":"2016","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.neo.2020.09.005_b0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114583","article-title":"PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma","volume":"9","author":"Karpel-Massler","year":"2014","journal-title":"PLoS ONE"},{"issue":"30","key":"10.1016\/j.neo.2020.09.005_b0420","doi-asserted-by":"crossref","first-page":"20543","DOI":"10.1074\/jbc.M114.549220","article-title":"Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression","volume":"289","author":"Meng","year":"2014","journal-title":"J Biol Chem"},{"issue":"17","key":"10.1016\/j.neo.2020.09.005_b0425","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-13-0516","article-title":"PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy","volume":"19","author":"Yuan","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.neo.2020.09.005_b0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152584","article-title":"Activation of the PI3K\/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer","volume":"11","author":"Cardnell","year":"2016","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.neo.2020.09.005_b0435","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","article-title":"Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer","volume":"2","author":"Juvekar","year":"2012","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.neo.2020.09.005_b0440","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Disc"},{"issue":"24","key":"10.1016\/j.neo.2020.09.005_b0445","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","article-title":"Bortezomib-induced \u201cBRCAness\u201d sensitizes multiple myeloma cells to PARP inhibitors","volume":"118","author":"Neri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.neo.2020.09.005_b0450","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-020-0759-0","article-title":"Dual metabolic reprogramming by ONC201\/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma","author":"Pruss","year":"2020","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.neo.2020.09.005_b0455","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1238557","article-title":"Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma","volume":"5","author":"Deken","year":"2016","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.neo.2020.09.005_b0460","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.neo.2020.09.005_b0465","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1202390","article-title":"Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction","volume":"5","author":"Hendriks","year":"2016","journal-title":"Oncoimmunology"},{"issue":"14","key":"10.1016\/j.neo.2020.09.005_b0470","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1158\/1078-0432.CCR-15-2665","article-title":"CD44+ cells in head and neck squamous cell carcinoma suppress T-cell-mediated immunity by selective constitutive and inducible expression of PD-L1","volume":"22","author":"Lee","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.neo.2020.09.005_b0475","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.stem.2016.12.001","article-title":"Glioblastoma cancer stem cells evade innate immune suppression of self-renewal through reduced TLR4 Expression","volume":"20","author":"Alvarado","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"11","key":"10.1016\/j.neo.2020.09.005_b0480","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1038\/cdd.2016.92","article-title":"Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy","volume":"23","author":"Wang","year":"2016","journal-title":"Cell Death Differ"},{"issue":"3","key":"10.1016\/j.neo.2020.09.005_b0485","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.yrtph.2005.05.004","article-title":"The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s)","volume":"42","author":"Dorato","year":"2005","journal-title":"Regul Toxicol Pharm"},{"issue":"1","key":"10.1016\/j.neo.2020.09.005_b0490","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/neuonc\/noz164","article-title":"Biological activity of weekly ONC201 in adult recurrent glioblastoma patients","volume":"22","author":"Arrillaga-Romany","year":"2020","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neo.2020.09.005_b0495","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s40425-019-0599-8","article-title":"Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration","volume":"7","author":"Stein","year":"2019","journal-title":"J ImmunoTher Cancer"},{"issue":"15","key":"10.1016\/j.neo.2020.09.005_b0500","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1158\/1078-0432.CCR-16-2658","article-title":"First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors","volume":"23","author":"Stein","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.neo.2020.09.005_b0505","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjh.15271","article-title":"Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment","volume":"185","author":"Romaguera","year":"2019","journal-title":"Br J Haematol"},{"issue":"45","key":"10.1016\/j.neo.2020.09.005_b0510","doi-asserted-by":"crossref","first-page":"79298","DOI":"10.18632\/oncotarget.17837","article-title":"A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma","volume":"8","author":"Arrillaga-Romany","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.neo.2020.09.005_b0515","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11060-019-03271-3","article-title":"Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201","volume":"145","author":"Chi","year":"2019","journal-title":"J Neurooncol"},{"issue":"7384","key":"10.1016\/j.neo.2020.09.005_b0520","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.neo.2020.09.005_b0525","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nm.4296","article-title":"Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas","volume":"23","author":"Piunti","year":"2017","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.neo.2020.09.005_b0530","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1016\/j.neo.2020.09.005_b0535","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","article-title":"K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas","volume":"124","author":"Khuong-Quang","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.neo.2020.09.005_b0540","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5414\/NP301085","article-title":"H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis","volume":"37","author":"Kleinschmidt-DeMasters","year":"2018","journal-title":"Clin Neuropathol"},{"issue":"1","key":"10.1016\/j.neo.2020.09.005_b0545","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/nox149","article-title":"Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location","volume":"20","author":"Karremann","year":"2018","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.neo.2020.09.005_b0550","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ng.1102","article-title":"Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas","volume":"44","author":"Wu","year":"2012","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.neo.2020.09.005_b0555","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.humpath.2015.07.002","article-title":"The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults","volume":"46","author":"Feng","year":"2015","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.neo.2020.09.005_b0560","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11912-020-0877-0","article-title":"Targeting and therapeutic monitoring of H3K27M-mutant glioma","volume":"22","author":"Wierzbicki","year":"2020","journal-title":"Curr Oncol Rep"},{"issue":"19","key":"10.1016\/j.neo.2020.09.005_b0565","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2017.75.9308","article-title":"Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG registries","volume":"36","author":"Hoffman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.neo.2020.09.005_b0570","article-title":"Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma","volume":"38","author":"Arrillaga-Romany","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.neo.2020.09.005_b0575","article-title":"Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma","volume":"38","author":"Kawakibi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.neo.2020.09.005_b0580","doi-asserted-by":"crossref","first-page":"10046","DOI":"10.1200\/JCO.2019.37.15_suppl.10046","article-title":"ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma","volume":"37","author":"Gardner","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.neo.2020.09.005_b0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/2019.2.PEDS18480","article-title":"First clinical experience with DRD2\/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report","volume":"23","author":"Hall","year":"2019","journal-title":"J Neurosurg Pediatr"},{"issue":"24","key":"10.1016\/j.neo.2020.09.005_b0590","doi-asserted-by":"crossref","first-page":"12728","DOI":"10.18632\/oncotarget.2890","article-title":"The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity","volume":"5","author":"Wagner","year":"2014","journal-title":"Oncotarget"},{"issue":"13 Suppl","key":"10.1016\/j.neo.2020.09.005_b0595","article-title":"Defining structure activity relationships for GPCR engagement and anti-cancer efficacy of imipridone small molecules","volume":"79","author":"Prabhu","year":"2019","journal-title":"Cancer Res"},{"issue":"13 Suppl","key":"10.1016\/j.neo.2020.09.005_b0600","article-title":"IND-enabling characterization of DRD2\/3 imipridone antagonist ONC206 for oncology","volume":"79","author":"Prabhu","year":"2019","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.neo.2020.09.005_b0605","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092436","article-title":"Targeting dopamine receptor D2 by imipridone suppresses uterine serous cancer malignant phenotype","volume":"12","author":"Hu","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"Supplement_6","key":"10.1016\/j.neo.2020.09.005_b0610","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noz175.401","article-title":"EXTH-71. Ind-enabling characterization of ONC206 as the next bitopic DRD2 antagonist for neuro-oncology","volume":"21","author":"Prabhu","year":"2019","journal-title":"Neuro-Oncology"},{"issue":"4","key":"10.1016\/j.neo.2020.09.005_b0615","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1535-6108(02)00058-2","article-title":"Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene","volume":"1","author":"Le","year":"2002","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.neo.2020.09.005_b0620","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1038\/s41375-019-0491-z","article-title":"Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia","volume":"33","author":"Nii","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.neo.2020.09.005_b0625","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/1087057113475480","article-title":"Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors","volume":"18","author":"Southern","year":"2013","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.neo.2020.09.005_b0630","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.11688","article-title":"Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia","author":"Bond","year":"2016","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.neo.2020.09.005_b0635","doi-asserted-by":"crossref","first-page":"12334","DOI":"10.1073\/pnas.95.21.12334","article-title":"A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2\/M","volume":"95","author":"Weng","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.neo.2020.09.005_b0640","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1161\/CIRCRESAHA.108.181131","article-title":"G2A deficiency in mice promotes macrophage activation and atherosclerosis","volume":"104","author":"Bolick","year":"2009","journal-title":"Circ Res"},{"issue":"16","key":"10.1016\/j.neo.2020.09.005_b0645","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1074\/jbc.M209101200","article-title":"The lysophospholipid receptor G2A activates a specific combination of G proteins and promotes apoptosis","volume":"278","author":"Lin","year":"2003","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.neo.2020.09.005_b0650","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/s41467-019-09981-6","article-title":"PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism","volume":"10","author":"Jain","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.neo.2020.09.005_b0655","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/neuonc\/noz058","article-title":"EZHIP\/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma","volume":"21","author":"Hubner","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neo.2020.09.005_b0660","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaa215.022","article-title":"Epidermal Growth Factor Receptor (EGFR) as a molecular determinant of glioblastoma response to dopamine receptor 2 (DRD2) inhibitors","author":"He","year":"2020","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.neo.2020.09.005_b0665","doi-asserted-by":"crossref","DOI":"10.1080\/15384101.2017.1325046","article-title":"Preclinical evaluation of the imipridone family, analogues of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212","author":"Wagner","year":"2017","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/j.neo.2020.09.005_b0670","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1124\/mol.109.062018","article-title":"PAR1 and PAR2 couple to overlapping and distinct sets of G proteins and linked signaling pathways to differentially regulate cell physiology","volume":"77","author":"McCoy","year":"2010","journal-title":"Mol Pharmacol"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558620301512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558620301512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:08:19Z","timestamp":1761484099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558620301512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":134,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1476558620301512"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2020.09.005","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ONC201 and imipridones: Anti-cancer compounds with clinical efficacy","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2020.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}